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Abstract
The electronic surveillance system Hema e-Chart allowed us to prospectively collect data and to perform an analysis of invasive fungal
infections (IFI) diagnosed in febrile patients as well as the procedures allowing their diagnosis and outcome according to the treatment
given. Every patient admitted to 26 Italian Haematology Units with a new diagnosis of haematological malignancy and who was a candi-
date for chemotherapy was consecutively registered between March 2007 and March 2009. In all, 147 haematological patients with
mycoses were identified. Yeasts were found in 23 infections; moulds were diagnosed in 17 proven, 35 probable and 72 possible myco-
ses. Galactomannan (GM) antigen was the most important test to diagnose probable mould infection; it was positive (cut-off >0.5) in 27
(77%) probable and in nine (53%) proven mould infections. Among patients with probable/proven mould infection who received no pro-
phylaxis or non-mould-active prophylaxis with fluconazole, more patients (n = 26, 78.8%) had GM antigen positivity compared with
patients (n = 10, 52.6%) given prophylaxis with mould-active drugs (p <0.05). First-line antifungal therapy was effective in 11/23 (48%)
yeast infections and in 37/52 (71.2%) proven/probable mould infections. Twenty patients (14%) died within 12 weeks. The fungal attrib-
utable mortality was 30.4% and 17.3% in yeast and proven/probable mould infections, respectively. Among risk factors only age was
independently associated (p 0.013) with mortality; sex, underlying haematological malignancy, previous prophylaxis and presence of neu-
tropenia at diagnosis were not significant. A diagnosis of mould infection seemed to have a trend for a better outcome than the diagno-
sis of yeast infection (p 0.064).
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Introduction
Invasive mycoses are a major cause of morbidity and mortal-
ity in haematological malignancies. Even if survival in mould
infections is improving [1–4], they continue to represent a
serious complication not only during allogeneic haematopoi-
etic stem cell transplant (HSCT) procedures but also during
the management of haematological cancers, in particular
acute leukaemia. Yeast infections appear to be decreasing
[1], probably because of the wide utilization of azole prophy-
laxis, but they still remain a significant problem in HSCT
recipients [5,6]. These data mainly derive from retrospective
epidemiological studies, which refer to patient populations
treated more than 5 years ago. The Hema e-Chart Registry
[7–10] is an electronic surveillance system that allows the
prospective collection and analysis of data regarding febrile
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events at first diagnosis in a large number of haematological
centres. It allows collection of up-to-date information about
risk factors and evaluation of the management of fungal infec-
tions in current clinical practice. In particular, close monitor-
ing allowed verification of the correct diagnostic procedures
of fungal infection and completion of a more accurate fol-
low-up of these patients. Herein we report an analysis of the
type of IFI diagnosed in febrile patients as well as the proce-
dures allowing their diagnosis and their outcome according
to the treatment given.
Patients and Methods
In the Hema e-Chart Registry every patient admitted to 26
Italian Haematology Units with a new diagnosis of haemato-
logical malignancy and who was a candidate for chemother-
apy was consecutively registered between March 2007 and
March 2009. Data were introduced prospectively into elec-
tronic case report forms as previously reported [7–10].
The Hema e-Chart Registry was approved by the Ethics
Committee of each participating centre. For each febrile epi-
sode baseline characteristics were collected and data were
updated every 3 days. The diagnostic work-up was similar
among all participating centres and included: cultures from
blood and from other sites such as nasal, pharyngeal and rec-
tal swabs, serological markers for invasive fungal disease, and
chest computed tomography scan within 4–7 days of fever.
Additional tests, such as bronchoalveolar lavage, sinus or
brain computed tomography scan, abdominal ultrasound, skin
biopsy or fundoscopy, were performed according to clinical
signs and symptoms. At the end of the fever episode the
investigator specified a diagnosis selecting from among these
possibilities: fever of unknown origin; bacterial, fungal or viral
fever; fever due to non-infectious causes. All IFI were then
centrally reviewed by the scientific Advisory Board and clas-
sified according to European Organization for Research and
Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
criteria [11]. Failure to respond was defined as progressive
or unchanged clinical or radiological parameters compared
with the baseline.
Overall mortality included all deaths that occurred within
12 weeks after the start of antifungal therapy. Attributable
mortality was considered as death in a patient with docu-
mented radiological, microbiological or histological findings
suggestive of active fungal infection with no response to
treatment and if other potential causes of death could be
excluded by the physician responsible for the patient.
Data were analysed by the usual descriptive techniques.
Categorical variables were studied by Pearson’s chi-squared
test, or by Fisher’s exact test, if needed. Survivorships were
analysed using the Kaplan–Meier product limit method fol-
lowed by a log-rank test in the case of categorical variables,
or by a Cox regression in the case of continuous or ordinal
variables. Statistical significance was assumed for p <0.05.
Results
In the Hema e-Chart Registry 147 haematological patients
with mycoses (72 possible, 35 probable and 40 proven) were
identified. There were 91 men, median age 60 years (range
18–84 years). The majority of patients had acute myeloid
leukaemia (81.6%) and >90% (133/147) were severely neu-
tropenic (absolute neutrophil count <0.5 · 109/L) at the time
of symptom onset. The epidemiological and clinical charac-
teristics of patients are represented in Table 1.
Aetiological agents
Regarding causative pathogens, yeasts were identified in 23
infections and moulds in 52 probable/proven infections, with
a yeast/mould ratio of 1/2.2. In addition, in 72 patients the
criteria for a diagnosis of possible IFI of the lung were met.
TABLE 1. Demographic characteristics and clinical out-
comes of our population
Patients, n 147
Age, years (range) 60 (18–84)
Sex (F/M) 56/91
Acute myeloid leukaemia 120 (82%)
Acute lymphoid leukaemia 10
Chronic lymphoid leukaemia 2
Non-Hodgkin’s lymphoma 8
Multiple myeloma 4
Myelodysplastic syndromes 3
Profound neutropenia (<0.5 · 109/L) 133 (90.4%)
Prophylaxis 83 (56%)
Itraconazole 46
Fluconazole 25
Posaconazole 6
Liposomal amphotericin 3
Voriconazole 2
Caspofungin 1
Response to first-line antifungal treatment
Yeasts (no. of patients): 23
Fluconazole 3/5
Caspofungin 4/9
Amphotericin B and its lipidic formulations 4/8
Voriconazole 0/1
Moulds (no. of patients, proven/probable): 52
Caspofungin 9/13
Amphotericin B and its lipidic formulations 15/20
Voriconazole 12/16
Combination therapya 0/1
Fluconazole (empirical treatment) 0/2
Deaths due to mycosis in patients
With yeasts 7/23
With possible moulds 4/72
With proven/probable moulds 9/52
IFI-attributable mortality
Yeasts 30.4%
Moulds (proven/probable) 17.3%
IFI, invasive fungal infection.
aliposomal amphotericin + caspofungin.
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Among yeasts, Candida was the main aetiological agent
detected by culture (six C. albicans, five C. krusei, four
C. parapsilosis and three Candida spp.) with a predominance
of Candida non-albicans; Candida spp. was also present in
urine cultures of two severely neutropenic patients with col-
onization in other sites, and in a patient with hepatosplenic
localization. Finally, two yeast infections were caused by
Blastoschizomyces capitatus in blood culture and Histoplasma
capsulatum diagnosed by gastroenteric tract biopsy.
Among moulds, we found 17 proven, 35 probable and 72
possible mycoses, according to EORTC-MSG criteria. Chest
computed tomography scan was suggestive for mould infec-
tion in the 72 ‘possible’ patients and in 48/52 probable or
proven patients. Four patients had rhinosinusal localization,
10 had disseminated disease.
Diagnostic procedures
Proven mould diagnoses were obtained by biopsy in 14
patients (two Aspergillus flavus, two Aspergillus fumigatus, one
Aspergillus spp., one Rizhopus spp, eight moulds species), by
culture of sterile fluid (A. fumigatus) in one and by blood cul-
ture (Fusarium spp. and Acremonium spp.) in two cases. In
one case nasal swab was positive for A. fumigatus. Criteria
for probable mould infection were present in 35 patients.
The GM antigen in the serum was the most important test
to diagnose probable mould infection; it was positive (cut-off
>0.5) in 27 (77%) probable and in nine (53%) proven mould
infections. The b-glucan antigen was positive in one patient.
In seven cases moulds grew in bronchoalveolar lavage (two
A. fumigatus, one A. flavus, one A. niger, three Aspergillus spp.),
and hyphae were found in one cytological examination from
bronchoalveolar lavage.
Antifungal treatments
In our study population 83 patients (56%) were on systemic
antifungal prophylaxis at the diagnosis of fungal infection.
Seven of these had breakthrough yeast infections by C. krusei
[3], C. albicans [1], C. parapsilosis [1], Candida spp. [1], or
Histoplasma capsulatum [1] during prophylaxis with fluconaz-
ole (five patients) and itraconazole (two patient). Most of
the yeast infections (16/23, 70%) occurred in patients who
had not received any systemic prophylaxis. Proven/probable
mould infections were diagnosed in 29.7% (19/64) of patients
receiving active anti-mould prophylaxis (itraconazole 18 cases
and caspofungin one case) and in 39.7% (33/83) of patients
not receiving active anti-mould prophylaxis (Table 2).
The correlation of the type of prophylaxis with the posi-
tivity of GM antigenemia and therefore its possible impact
on the diagnosis of mould infection was evaluated. As shown
in Table 2, among 33 patients with probable/proven mould
infection developed while receiving either no prophylaxis or
non-mould-active prophylaxis with fluconazole, 26 were GM
positive (78.8%), whereas among 19 patients with probable/
proven mould infection diagnosed while receiving mould-
active agents as prophylaxis (itraconazole or caspofungin)
only ten (52.6%) were GM positive (p <0.05).
The median time from the beginning of fever and treat-
ment initiation was 5 days (range 1–29). The response to
first-line antifungal treatment is reported in Table 1. Yeasts
failed to respond to first-line therapy in 12/23 cases (52%).
Among 52 patients with proven/probable mould infections
failure of first-line treatment was observed in 15/52 (28.8%).
Outcome
All 143 patients were evaluable for mortality within
12 weeks and 20 of them died (14%). Six patients died from
yeast infection and one patient from both yeast infection and
heart failure. Among patients with mould infections there
were 13 deaths, four in 72 possible (5.5%) and nine in 52
probable or proven mycoses (17.3%) (Table 1). None of the
patients with infections caused by rare moulds died.
The fungus-attributable mortality was 30.4% and 17.3% for
yeasts and proven/probable moulds, respectively. Overall
survival of our entire population and of patients with yeast
and mould infections are shown in Fig. 1.
TABLE 2. Galactomannan positivity in patients with mould
infections according to the type of prophylaxis
Prophylaxis
Possible
mould
infections
Probable/proven
mould infections
Probable/proven
mould infections
with galactomannan +
No prophylaxis 27 21 17
Fluconazole 9 12 9
Mould inactive 36 33 26 (78.8%)
Itraconazole 36 18 9
Caspofungin 0 1 1
Mould active 36 19 10 (52.6%)
FIG. 1.Overall survival of the entire population and of yeasts and
moulds.
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Prognostic factors
The potential prognostic factors for mortality (sex, age,
acute leukaemia versus other haematological cancers, antifun-
gal prophylaxis versus not, yeasts versus moulds, neutropenia
at diagnosis versus no neutropenia) were evaluated by uni-
variate and multivariate analysis (Table 3) Only age was inde-
pendently associated (p 0.013) with mortality within
12 weeks from the start of antifungal therapy. A diagnosis of
mould infection seemed to have a trend for a better out-
come than the diagnosis of a yeast infection (Fig. 1).
Discussion
The collection of data from the Hema e-Chart Registry
allows us to confirm prospectively our previously published
retrospective data [1,4] and also to highlight some observa-
tions regarding the current clinical practice in the manage-
ment of fungal infections by haematologists. As the majority
of findings regarding mycoses came from studies of selected
HSCT patients, they may not be applicable to patients with
leukaemia or lymphoma who did not undergo HSCT and had
different host characteristics. Our study confirms some well-
known epidemiological data. At the onset of mycosis the
majority of patients were severely neutropenic, showing that
neutropenia continues to be an important risk factor for fun-
gal disease in haematological cancers. Mould infection is a
persistent problem in treating haematological patients, above
all in acute leukaemia. In fact, in our population >80% of IFI
were diagnosed in acute myeloid leukaemia patients, con-
firming that these patients are correctly defined as at ‘high
risk’ for mycosis. In the other haematological malignancies
mould infections were more sporadic. The main site of
mould disease remains the lung (>90% of the patients),
whereas disseminated mould disease was quite a rare event
(8%), probably because empirical antifungal therapy and early
diagnostic work-up usually scheduled by the Registry partici-
pating centres [8] avoided a disastrous dissemination. The
diagnosis of proven mould infection represented a difficult
problem also in this prospective survey. Among the 124
patients with suspected aspergillosis, infection was proven in
only 13.7% of cases and was considered ‘probable’ according
to EORTC criteria in a further 28.2% of cases. In these
patients the diagnosis of aspergillosis relied on the detection
of GM antigenemia in over 75% of cases (27/35 patients),
showing that GM antigenemia is by far the most important
test for obtaining a microbiological criterion for diagnosis in
routine clinical practice.
Of note, our data further show that the type of antifungal
prophylaxis given was correlated with the level of IFI diag-
nostic evidence. In fact we obtained a GM test positivity in a
significantly lower proportion of proven/probable mould
infections when mould-active prophylaxis like itraconazole
was used. These data indirectly confirm that the positivity of
GM antigen could also depend on the administration of
systemic antifungal agents effective against Aspergillus such as
itraconazole or posaconazole currently used in prophylaxis,
as previously published by Marr et al. [12]. Given the key
diagnostic importance of GM antigenemia for the identifica-
tion of probable IFI, as shown also in this study, a reduced
sensitivity of GM antigenemia in patients undergoing mould-
active prophylaxis may cause an underdiagnosis of cases of
invasive aspergillosis, by classifying them as merely possible
IFI, potentially leading to insufficient antifungal treatment.
Although cultures were difficult to grow, the rare moulds
diagnosed in our population (Fusarium and Acremonium from
blood, Rhizopus from bronchoalveolar lavage) were actually
identified by cultures, underlining the importance of cultivat-
ing every probable fungal material to achieve a diagnosis of
species, which can respond differently to various antifungal
agents. As in our previous studies [1,13], rare moulds contin-
ued to be rare, constituting only 2% of the entire group of
mycoses; instead mould spp. were a frequent diagnosis,
probably because of the histological difficulty of distinguishing
the characteristics of hyphae between Aspergillus and Mucor.
Yeasts represented 15.6% of our mycoses, but they were
the largest group of proven infections (57%) (23 yeasts ver-
sus 17 moulds) thanks to the possibility of isolating and culti-
vating them from blood. Yeasts remain a persistent problem
in patients with acute leukaemia. Although azole prophylaxis
seemed to perform better against yeasts than against moulds,
because the majority of yeast infections occurred in patients
not receiving prophylaxis, 30% of yeast infections occurred
despite prophylaxis, in three cases as the result of resistance
of C. glabrata to azoles.
Response to first-line antifungal therapy was better in
mould than in yeast infections; in particular the favourable
therapeutic response in the mould infections was similar
using various antifungal agents (Table 1); this result differs
TABLE 3. Risk factors for mortality, multivariate analysis
Hazard
ratio SE z p >|z| 95% CI
Sex 1.595795 0.941039 0.79 0.428 0.5023705–5.06908
Age 1.07953 0.0332037 2.49 0.013 1.016375–1.14661
Haematological
disease
1.833344 1.377783 0.81 0.420 0.4202955–7.997114
Prophylaxis
vs none
1.045488 0.5742785 0.08 0.935 0.3562543–3.068157
Moulds vs
yeasts
0.3695466 0.1989072 )1.85 0.064 0.1286805–1.061269
Neutropenia 0.5942412 0.5406876 )0.57 0.567 0.0998785–3.53552
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from that reported in a recent study [14] regarding invasive
aspergillosis in haematological malignancies and HSCT recipi-
ents, in which the novel anti-mould azoles voriconazole and
posaconazole seem to confer a significant advantage, either
as primary or salvage therapy, over the lipid amphotericin-
containing regimens. However, in that population two char-
acteristics may be taken into consideration: the first being
that the patients were retrospectively included between June
1993 and June 2008, a long period during which the new
anti-mould azoles and caspofungin were not always available;
the second that the population included also allogeneic trans-
plant recipients, in which response to therapy and mortality
seem until now worse than in non-transplanted haematologi-
cal patients [15].
A third of the patients responded to a second-line therapy
in both types of mycoses, irrespective of which antifungal
drug was administered. In haematological malignancies the
Italian SEIFEM experience has shown a progressive improve-
ment of results in the last decade [1,4] both regarding the
response to antifungal therapy and the mortality due to
moulds. In yeast infections attributable mortality was compa-
rable to that reported in the literature and in our retrospec-
tive study [1], being similar in both haematological and
intensive-care unit patients [16,17], and it has remained con-
stant over the years. On the contrary, also in this prospec-
tive study, attributable mortality for aspergillosis seemed to
be further decreasing (17.3%) confirming the results of our
more recent retrospective study regarding aspergillosis in
acute myeloid leukaemia, performed between 2004 and 2007
[4], in which attributable mortality was reduced compared
with the previous study performed between 1999 and 2003
(27% versus 39%) [1]. In our population statistical studies
showed that the diagnosis of mould had a more favourable
trend for survival than the diagnosis of yeast (Fig. 1).
Decreasing mortality in aspergillosis was recently reported
also in a French single institution study [18]; probably
patients treated in more recent years may have had better
outcomes because of new developments in diagnosis and
early treatment with new antifungal drugs [19]. On the con-
trary, diagnosis of yeast has remained difficult until now,
based mainly on blood cultures, which are positive in only
half of patients. This possible delay of diagnosis could trans-
late into a delay also in therapy administration and may
explain the reduced efficacy of antifungal treatment against
yeasts.
In summary, this prospective study confirmed that patients
with acute leukaemia were the most frequent candidates for
fungal infections, particularly moulds, more rarely yeast infec-
tions also in patients receiving prophylaxis. In current clinical
practice diagnosis was obtained mainly by GM antigen and its
positivity increased in the absence of systemic mould-active
antifungal prophylaxis, which may therefore significantly mod-
ify the sensitivity of the diagnostic criteria of probable IFI. In
our population no particular risk factors for mortality were
identified except age, but a trend was present in favour of
higher mortality from yeast infections compared with mould
infections. Finally, also this more recent prospective observa-
tional study in non-transplanted haematological patients, like
our previous retrospective studies, confirmed that mortality
due to fungal infections, in particular due to moulds, seems
to have fallen over recent years.
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